StockNews.com Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Stock analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their target price on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Trading Up 15.3 %

Shares of NASDAQ APVO opened at $0.31 on Friday. Aptevo Therapeutics has a 52 week low of $0.14 and a 52 week high of $10.80. The business’s 50 day moving average price is $0.22 and its 200 day moving average price is $0.41.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.